The Goldman Sachs Group Initiates Coverage on Esperion Therapeutics (NASDAQ:ESPR)

Research analysts at The Goldman Sachs Group assumed coverage on shares of Esperion Therapeutics (NASDAQ:ESPR) in a report released on Wednesday, Marketbeat.com reports. The firm set a “neutral” rating and a $4.00 price target on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price objective points to a potential upside of 84.33% from the company’s current price.

Other equities analysts have also issued research reports about the stock. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Needham & Company LLC reissued a “buy” rating and set a $6.00 price objective on shares of Esperion Therapeutics in a research note on Friday, December 13th. Cantor Fitzgerald began coverage on Esperion Therapeutics in a report on Tuesday. They set an “overweight” rating and a $8.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Thursday, December 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $7.30.

Esperion Therapeutics Price Performance

NASDAQ ESPR opened at $2.17 on Wednesday. The company has a market cap of $427.57 million, a P/E ratio of -3.39 and a beta of 1.01. Esperion Therapeutics has a 12 month low of $1.58 and a 12 month high of $3.94. The company has a 50-day moving average of $2.41 and a 200-day moving average of $2.22.

Institutional Investors Weigh In On Esperion Therapeutics

Several large investors have recently made changes to their positions in the business. BOKF NA purchased a new stake in Esperion Therapeutics during the 2nd quarter worth $26,000. Traphagen Investment Advisors LLC acquired a new position in shares of Esperion Therapeutics during the third quarter worth about $27,000. Xponance Inc. acquired a new stake in shares of Esperion Therapeutics in the second quarter valued at about $28,000. National Bank of Canada FI raised its holdings in shares of Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 10,225 shares during the period. Finally, Sivia Capital Partners LLC acquired a new position in Esperion Therapeutics during the 2nd quarter worth approximately $44,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.